-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 AUhrTMmzP+NdTb0jEJyp+I9QaOe+cIfrY/oJT8qJKbiun7czsDMO1wg1zvikwP39
 sj4XeW8d80FGx8bjNOB2zg==

<SEC-DOCUMENT>0001325310-09-000025.txt : 20090507
<SEC-HEADER>0001325310-09-000025.hdr.sgml : 20090507
<ACCEPTANCE-DATETIME>20090506184554
ACCESSION NUMBER:		0001325310-09-000025
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20090427
FILED AS OF DATE:		20090507
DATE AS OF CHANGE:		20090506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALDA Pharmaceuticals Corp.
		CENTRAL INDEX KEY:			0001355736
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51848
		FILM NUMBER:		09802984

	BUSINESS ADDRESS:	
		STREET 1:		635 COLUMBIA STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E1T9
		BUSINESS PHONE:		6045218300

	MAIL ADDRESS:	
		STREET 1:		635 COLUMBIA STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E1T9
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k090427aph_swineflu.htm
<DESCRIPTION>BULLETIN SWINE FLU DATED APRIL 27, 2009
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>OMB APPROVAL</TITLE>
<META NAME="author" CONTENT="Your User Name">
<META NAME="date" CONTENT="05/06/2009">
</HEAD>
<BODY style="line-height:12pt; font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:864px"><P style="margin:0px"><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR height=0 style="font-size:0"><TD width=663.2></TD><TD width=184></TD></TR>
<TR><TD style="border-right:1px solid #000000" valign=top width=663.2><P>&nbsp;</P></TD><TD style="border-top:1px solid #000000; border-right:1px solid #000000; border-bottom:1px solid #000000" valign=top width=184><P style="line-height:10pt; margin-top:1.8px; margin-bottom:0px; font-family:Arial; font-size:8pt" align=center>OMB APPROVAL</P>
</TD></TR>
<TR><TD style="border-right:1px solid #000000" valign=top width=663.2><P>&nbsp;</P></TD><TD style="border-right:1px solid #000000; border-bottom:1px solid #000000" valign=top width=184><P style="line-height:10pt; margin-top:1.8px; margin-bottom:0px; font-family:Arial; font-size:8pt" align=right>OMB Number: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3235-0116<BR>
Expires: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;March 31, 2011<BR>
Estimated average burden &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="color:#FFFFFF; background-color:#FFFFFF">.<BR>
</FONT>hours per response &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.7</P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="line-height:18pt; margin:0px; font-size:16pt" align=center><B>UNITED STATES</B></P>
<P style="line-height:18pt; margin:0px; font-size:16pt" align=center><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P style="line-height:18pt; margin:0px; font-size:16pt" align=center><B>Washington, D.C. 20549</B></P>
<P style="margin:0px" align=center><BR></P>
<P style="line-height:16pt; margin:0px; font-size:14pt" align=center><B>Form 6-K</B></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px">For the month of <B><U>&nbsp;April 2009</U></B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px">Commission File Number: <B><U>51848</U></B></P>
<P style="margin:0px" align=center><BR></P>
<P style="line-height:13pt; margin:0px; font-size:11pt" align=center><B><U>ALDA Pharmaceuticals Corp.</U></B></P>
<P style="margin:0px" align=center>(Translation of registrant&#146;s name into English)</P>
<P style="line-height:13pt; margin-top:6.133px; margin-bottom:0px; font-size:11pt" align=center><B><U>635 Columbia St. New Westminster, B.C., Canada, V3M 1A7</U></B></P>
<P style="margin:0px" align=center>(Address of principal executive office)</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</P>
<P style="margin:0px">Form 20-F [X]<FONT style="font-family:Arial"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;Form 40-F <FONT style="font-family:Arial">&#56256;&#56453;</FONT></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=justify><B>Note: </B>Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px">Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P style="margin:0px">Yes <FONT style="font-family:Arial">&#56256;&#56453;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No [X]</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): &nbsp;&nbsp;82-_______________.</P>
<P style="margin:0px" align=center><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR height=0 style="font-size:0"><TD width=80.6></TD><TD width=539.4></TD></TR>
<TR><TD valign=top width=80.6><P style="margin:0px"><B><U>Exhibit No.</U></B></P>
</TD><TD valign=top width=539.4><P style="margin:0px"><B><U>Document</U></B></P>
</TD></TR>
<TR><TD width=80.6><P style="margin-top:0px; margin-bottom:5.533px" align=center>1</P>
</TD><TD width=539.4><P style="margin-top:0px; margin-bottom:5.533px; color:#0000FF"><A HREF="#bulletin"><U>April 27, 2009 Bulletin &#8211; Swine Flu</U></A><FONT style="color:#000000"></FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><B>SIGNATURES</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>
<P style="margin:0px"><BR></P>
<P style="line-height:normal; margin:0px; text-indent:384px; font-size:11pt"><B>ALDA Pharmaceuticals Corp.</B><FONT style="font-size:10pt"> </FONT></P>
<P style="margin:0px">Date:<U> May 6, 2009 &nbsp;&nbsp;&nbsp;</U></P>
<P style="margin-top:0px; margin-bottom:-16px; text-indent:360px">By: </P>
<P style="margin:0px; text-indent:408px">&#147;<FONT style="color:#00007F"><B><I>Terrance G. Owen</I></B></FONT>&#148;</P>
<P style="margin:0px"><BR></P>
<P style="margin-top:0px; margin-bottom:-16px">&nbsp;&nbsp;</P>
<P style="margin-top:0px; margin-bottom:-16px; text-indent:360px">Name:</P>
<P style="margin:0px; text-indent:408px">Terrance G. Owen, Ph.D., M.B.A.</P>
<P style="line-height:20pt; margin-top:0px; margin-bottom:-26.667px; text-indent:360px">Title: </P>
<P style="line-height:18pt; margin:0px; text-indent:408px">President &amp; CEO</P>
<P style="line-height:18pt; margin:0px; padding-bottom:4px; border-bottom:4px groove #000000"><BR></P>
<P style="line-height:18pt; margin:0px"><BR></P>
<P style="line-height:18pt; margin:0px"><BR></P>
<P style="line-height:18.6pt; margin-top:0px; margin-bottom:16.8px" align=center><BR></P>
<P style="line-height:18.6pt; margin-top:0px; margin-bottom:16.8px; font-size:12pt; page-break-before:always" align=center><B>ALDA PHARMACEUTICALS CORP.</B></P>
<P style="line-height:12.6pt; margin:0px; font-size:12pt" align=center><B>635 Columbia Street<BR>
New Westminster, British Columbia V3M 1A7</B></P>
<P style="line-height:20pt; margin:0px; padding-left:-6px; font-size:12pt" align=center><B>Tel: (604) 521-8300 Fax: (604) 521-8322<BR>
BULLETIN</B></P>
<P style="margin:0px" align=center><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR height=0 style="font-size:0"><TD width=439.2></TD><TD width=439.2></TD></TR>
<TR><TD valign=top width=439.2><P style="line-height:20pt; margin:0px; font-size:12pt"><B>TSX-V: APH &amp; OTCBB:APCSF</B></P>
</TD><TD valign=top width=439.2><P style="line-height:20pt; margin:0px; font-size:12pt" align=right><B>April 27, 2009</B></P>
</TD><A NAME="bulletin"></A></TR>
</TABLE>
<P style="line-height:14pt; margin:0px; font-size:12pt" align=center><B>SWINE FLU</B></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px">The current &#147;swine flu&#148;, which is creating concerns about the possibility of a new pandemic, is caused by a new form of the Influenza A virus which shows characteristics of swine, avian and human viruses. Swine flu does not normally infect humans but a major pandemic occurred in 1918 when approximately 500 million people were infected worldwide and 50 million died. Since then, there have been other occurrences of swine flu but, prior to the current outbreak, only a small number of people were infected.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px">Historically, there have been approximately 3 influenza pandemics in each century for the last 300 years. The most recent ones were the Asian Flu in 1957 and the Hong Kong Flu in 1968. In recent years, the global focus for a pandemic has shifted to the H5N1 bird flu virus, which has spread from poultry to humans, especially in Asia but The World Health Organization has now also identified swine influenza as a potential source of a human flu pandemic.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px">Health organizations in Canada and the US have published recommendations on how to reduce the transmission of swine flu. These include washing your hands thoroughly with soap and warm water or hand sanitizer, covering your mouth when coughing and sneezing, keep doing what you normally do but stay home if you're sick and talk to your doctor if you experience flu-like symptoms.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><B>About ALDA Pharmaceuticals Corp.</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px">ALDA is focused on the development of infection-control therapeutics derived from its patented T<SUP>3</SUP>6<SUP>&#174;</SUP> technology. T<SUP>3</SUP>6<SUP>&#174;</SUP> has been proven to be effective against the H1N1 and H3N2 strains of swine flu and against SARS-like viruses. The company trades on the TSX Venture Exchange under the symbol, &#147;APH&#148;, and is quoted on the OTCBB under the symbol, &#147;APCSF&#148;.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px">Terrance G. Owen, Ph.D., MBA</P>
<P style="line-height:12.6pt; margin:0px; padding-right:268.8px">President &amp; CEO <BR>
ALDA Pharmaceuticals Corp.</P>
<P style="line-height:12.6pt; margin:0px; padding-right:268.8px; color:#0000FF"><B><I><U>www.aldacor<A NAME="_Hlt115846424"></A>p.com</U></I></B></P>
<P style="line-height:12.6pt; margin:0px"><BR></P>
<P style="line-height:12.6pt; margin:0px; padding-right:268.8px">Distribution &amp; Sales Contact<BR>
Peter Chen</P>
<P style="line-height:12.6pt; margin:0px; padding-right:268.8px">(604) 521- 8300 Ext. 3<BR>
<FONT style="color:#0000FF"><B><I><U>peter_chen@aldacorp.com</U></I></B></FONT></P>
<P style="line-height:12.6pt; margin:0px"><BR></P>
<P style="line-height:12.6pt; margin:0px; padding-right:268.8px">Investor Relations Contact</P>
<P style="line-height:12.6pt; margin:0px; padding-right:268.8px">Scott Young</P>
<P style="margin:0px">604-288-7222</P>
<P style="margin:0px; color:#0000FF"><B><I><U>syoung@freeformcom.com</U></I></B><FONT style="color:#000000"> </FONT></P>
<P style="line-height:12.6pt; margin:0px"><BR></P>
<P style="line-height:12.6pt; margin:0px"><I>Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.</I></P>
<P style="line-height:12.6pt; margin:0px"><BR></P>
<P style="line-height:12.6pt; margin:0px"><I>Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA&#146;s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as &#147;outlook,&#148; &#147;will,&#148; &#147;could,&#148; &#147;would,&#148; &#147;might,&#148; &#147;remains,&#148; &#147;to be,&#148; &#147;plans,&#148; &#147;believes,&#148; &#147;may,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;anticipates,&#148; &#147;estimate,&#148; future,&#148; &#147;plan,&#148; &#147;positioned,&#148; &#147;potential,&#148; &#147;project,&#148; &#147;remain,&#148; &#147;scheduled,&#148; &#147;set to,&#148; &#147;subject to,&#148; &#147;upcoming,&#148; and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the d
ate of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.</I></P>
<P style="line-height:18.6pt; margin-top:0px; margin-bottom:16.8px; font-size:12pt" align=center><B>&nbsp;</B></P>
<P style="line-height:18pt; margin:0px"><BR></P>
<P style="line-height:18pt; margin:0px"><BR></P>
</DIV></BODY>
<!-- EDGAR Validation Code: 1C524B18 -->
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
